Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Interventional Radiology

Advanced Medical and Surgical Interventions

At a Glance

For primary intestinal lymphangiectasia that persists despite a strict low-fat diet, specialist care may include octreotide or sirolimus, targeted embolization or surgery for focal leaks, and supportive albumin, TPN, or immunoglobulin when complications are severe.

While a strict low-fat diet is the primary treatment for primary intestinal lymphangiectasia (PIL), some patients find that diet alone is not enough to stop the “leak” of protein and immune cells [1][2]. When symptoms persist despite dietary adherence, doctors turn to medical, radiological, or surgical interventions to manage the condition [3][4].

These therapies are largely considered specialist, off-label treatments with limited PIL evidence based on small series and case reports.

Medical Therapies for Refractory Disease

If your protein levels remain dangerously low on a diet, your specialist may discuss medications that aim to reduce lymphatic flow or “quiet” the growth of malformed vessels.

  • Octreotide: This is a synthetic version of a hormone that can slow down the production of digestive juices and reduce blood flow to the gut [2]. Some case reports show that octreotide can help normalize albumin levels and reduce diarrhea [5][6]. However, its success is inconsistent; some patients do not respond, and others find the benefits are only temporary [3][7]. It carries risks of gastrointestinal effects, gallstones, and glucose abnormalities.
  • Sirolimus (Rapamycin): Originally used to prevent organ transplant rejection, sirolimus is now being used for various lymphatic “overgrowth” conditions [8]. It works by blocking a specific pathway (mTOR) that tells lymphatic vessels to grow [9]. In small studies, sirolimus has helped normalize lymphocyte counts and stop protein leakage, even in severe cases [10][3]. Because it suppresses the immune system, it requires close monitoring of drug levels in the blood [11]. Beyond drug levels, it requires monitoring for blood counts (cytopenias), renal/liver function, lipids, infection risk, mouth ulcers, and impaired wound healing.

Targeted Interventions: Embolization and Surgery

In some cases, the “leak” is not happening throughout the whole intestine but is coming from one specific, broken vessel or a short segment of the bowel [4].

Mapping the Leak

Before a procedure, doctors use advanced imaging like magnetic resonance lymphangiography (MRL) or CT lymphangiography to map the “plumbing” of your lymphatic system [4][12]. This helps them see exactly where the lymph is backing up or leaking into the gut [13].

Procedures

  • Lymphatic Embolization: A minimally invasive procedure performed by an interventional radiologist. Using a tiny catheter, the doctor “plugs” the leaking vessel with a medical glue or coil [14]. In selected case reports for a demonstrable focal leak, this specialized option has shown effectiveness, but it has procedural risks and is not a standard cure for diffuse PIL [14][3].
  • Surgical Resection: If the malformed vessels are confined to a very short segment of the small intestine (focal disease), a surgeon can remove that piece of the bowel [15]. This can lead to a full recovery, but it is rarely used for “diffuse” disease that affects large portions of the intestine [2][16].

Supportive Care for Severe Cases

In very severe or “refractory” cases, you may need intensive support to keep your body stable while other treatments are being adjusted.

  • Albumin Infusions and Diuretics: When blood protein (albumin) is extremely low, you may receive it through an IV to help pull fluid out of your tissues and back into your bloodstream [2]. Diuretics (water pills) are sometimes used alongside these infusions, but they are not automatically appropriate and can cause dangerous low blood pressure, kidney injury, and electrolyte abnormalities [17].
  • Total Parenteral Nutrition (TPN): If your gut is so damaged that it cannot absorb enough nutrients to keep you healthy, you may need “IV feeding” or TPN [18]. This delivers calories, proteins, and fats directly into a large vein, completely bypassing the digestive tract [19]. While TPN can be life-saving and allow the gut to “rest,” it is usually considered a temporary bridge to other treatments [20][18]. TPN carries central-line infection, thrombosis, liver, and metabolic risks.
  • Immunoglobulin Replacement: If your antibody levels (IgG) drop too low due to intestinal loss, your doctor may recommend IV or subcutaneous immunoglobulin (SCIG) infusions to help your body fight off infections [21][22]. This is considered based on the pattern of infections and antibody function—not an IgG number alone.

Common questions in this guide

When are advanced treatments considered for primary intestinal lymphangiectasia?
They are generally discussed when a strict low-fat diet does not stop protein loss or symptoms. The options depend on whether the leak is diffuse or comes from a small, identifiable area, and many are specialist or off-label treatments with limited evidence.
What should I know about octreotide for primary intestinal lymphangiectasia?
Octreotide can reduce digestive secretions and blood flow to the gut, which may reduce diarrhea and improve albumin levels in some patients. Its benefit is inconsistent or temporary for others. Possible problems include gastrointestinal effects, gallstones, and changes in blood sugar.
How is sirolimus used and monitored in PIL?
Sirolimus may slow abnormal lymphatic vessel growth by blocking a growth pathway called mTOR. Because it can suppress the immune system, clinicians monitor drug levels, blood counts, kidney and liver function, cholesterol and other fats, infection risk, mouth ulcers, and wound healing.
Could lymphatic embolization or surgery treat my intestinal lymphangiectasia?
Magnetic resonance or CT lymphangiography can help show where lymph is leaking. Embolization may close a clearly identified leaking vessel, while surgery may remove a short bowel segment with abnormal vessels. These approaches are more suitable for focal disease and are not a standard cure for diffuse disease.
When might albumin infusions, diuretics, or TPN be needed for PIL?
Albumin may be given through a vein when blood protein is extremely low, and diuretics may sometimes be used to manage fluid buildup with close supervision. Total parenteral nutrition, or TPN, may be needed when the intestine cannot absorb enough nutrition and is usually used as a temporary bridge. These treatments can cause blood pressure, kidney, electrolyte, infection, clotting, liver, and metabolic problems.
When is immunoglobulin replacement considered?
Immunoglobulin replacement may be considered when intestinal protein loss leads to low antibody levels together with frequent or severe infections or poor antibody function. The decision is based on the overall infection pattern and immune evaluation, not on an antibody level alone.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Primary intestinal lymphangiectasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my lymphangiectasia considered 'focal' (in one spot) or 'diffuse' (spread out), and what imaging was used to determine this?
  2. 2.If we are considering octreotide or sirolimus, what specific side effects should I watch for, and how often will we monitor my blood counts and organ function?
  3. 3.Am I a candidate for lymphatic imaging to map exactly where the lymph is leaking, and is embolization a realistic option for my anatomy?
  4. 4.How do we decide when my protein levels or volume status truly require an albumin infusion or diuretics?
  5. 5.If I need TPN, what is our long-term plan for minimizing liver and central-line infection risks?
  6. 6.Does my specific pattern of infections and antibody levels warrant a formal evaluation for immunoglobulin replacement?

References

References (22)
  1. 1

    Clinical presentation, treatment, and outcome of children with primary intestinal lymphangiectasia: A national retrospective study.

    Goret N, Lambe C, Ecochard-Dugelay E, et al.

    Journal of pediatric gastroenterology and nutrition 2026; (82(2)):398-406 doi:10.1002/jpn3.70266.

    PMID: 41277165
  2. 2

    Primary intestinal lymphangiectasia: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

    Vignes S, Uzzan M, Arrivé L, et al.

    Orphanet journal of rare diseases 2025; (20(1)):356 doi:10.1186/s13023-025-03657-9.

    PMID: 40640921
  3. 3

    Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature.

    Kwon Y, Kim ES, Choe YH, Kim MJ

    BMC pediatrics 2021; (21(1)):21 doi:10.1186/s12887-020-02447-5.

    PMID: 33407260
  4. 4

    The Update of Treatment for Primary Intestinal Lymphangiectasia.

    Kwon Y, Kim MJ

    Pediatric gastroenterology, hepatology & nutrition 2021; (24(5)):413-422 doi:10.5223/pghn.2021.24.5.413.

    PMID: 34557394
  5. 5

    Refractory primary intestinal lymphangiectasia effectively managed with subcutaneous octreotide.

    Halim A, Youd P, Thorpe J, Halim I

    BMJ case reports 2021; (14(4)) doi:10.1136/bcr-2020-238457.

    PMID: 33837021
  6. 6

    Endoscopic Diagnosis of Primary Intestinal Lymphangiectasia in an Adult With Refractory Protein-Losing Enteropathy: A Case Report.

    Khalil Z, Ali HN, Ibrahim H, Al-Abbedien EZ

    Cureus 2024; (16(8)):e66141 doi:10.7759/cureus.66141.

    PMID: 39233993
  7. 7

    Severe Refractory Anemia in Primary Intestinal Lymphangiectasia. A Case Report.

    Balaban VD, Popp A, Grasu M, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2015; (24(3)):369-73 doi:10.15403/jgld.2014.1121.243.bal.

    PMID: 26405709
  8. 8

    Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.

    Baluk P, Yao LC, Flores JC, et al.

    JCI insight 2017; (2(16)).

    PMID: 28814666
  9. 9

    Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights.

    Ozeki M, Fukao T

    Advances in wound care 2019; (8(6)):230-245 doi:10.1089/wound.2018.0850.

    PMID: 31236308
  10. 10

    Successful Early Therapy With Sirolimus for an Infant With Primary Intestinal Lymphangiectasia.

    Yamamoto S, Sugino Y, Yamashita T, et al.

    Case reports in pediatrics 2026; (2026()):7717714 doi:10.1155/crpe/7717714.

    PMID: 42751049
  11. 11

    Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial.

    Ozeki M, Endo S, Yasue S, et al.

    Frontiers in medicine 2024; (11()):1335469 doi:10.3389/fmed.2024.1335469.

    PMID: 38390569
  12. 12

    Correlation between capsule endoscopy classification and CT lymphangiography of primary intestinal lymphangiectasia.

    Zhao Q, Sun X, Liu K, et al.

    Clinical radiology 2023; (78(3)):219-226 doi:10.1016/j.crad.2022.10.001.

    PMID: 36509551
  13. 13

    Primary intestinal lymphangiectasia: Multiple detector computed tomography findings after direct lymphangiography.

    Sun X, Shen W, Chen X, et al.

    Journal of medical imaging and radiation oncology 2017; (61(5)):607-613 doi:10.1111/1754-9485.12606.

    PMID: 28345300
  14. 14

    Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia.

    Kwon Y, Kim ES, Choe YH, et al.

    Yonsei medical journal 2021; (62(5)):470-473 doi:10.3349/ymj.2021.62.5.470.

    PMID: 33908219
  15. 15

    Pediatric localized intestinal lymphangiectasia treated with resection.

    Mari J, Kovacs T, Pasztor G, et al.

    International medical case reports journal 2019; (12()):23-27 doi:10.2147/IMCRJ.S192940.

    PMID: 30804688
  16. 16

    Surgical therapy of primary intestinal lymphangiectasia in adults.

    Huber T, Paschold M, Eckardt AJ, et al.

    Journal of surgical case reports 2015; (2015(7)).

    PMID: 26169531
  17. 17

    Playing CATCH-up: a case report of profound protein-losing enteropathy and gastrointestinal haemorrhage from intestinal lymphangiectasia in DiGeorge syndrome.

    Carrigan L, Yap J, Cheung M

    European heart journal. Case reports 2026; (10(5)):ytag257 doi:10.1093/ehjcr/ytag257.

    PMID: 42125525
  18. 18

    Clinical Profile, Response to Therapy, and Outcome of Children with Primary Intestinal Lymphangiectasia.

    Prasad D, Srivastava A, Tambe A, et al.

    Digestive diseases (Basel, Switzerland) 2019; (37(6)):458-466 doi:10.1159/000499450.

    PMID: 31030202
  19. 19

    Home parenteral nutrition a life-saving therapy in a primary intestinal lymphangiectasia patient affecting the entire GI tract - 3 year follow-up case report.

    Mańkowska-Wierzbicka D, Kloska M, Karwowska K, et al.

    Annals of medicine and surgery (2012) 2021; (67()):102483 doi:10.1016/j.amsu.2021.102483.

    PMID: 34168874
  20. 20

    Adult-Onset Primary Intestinal Lymphangiectasia With Liver Enzymes Elevation.

    Nguyen CD, Buchman A, Bui HH, et al.

    ACG case reports journal 2022; (9(12)):e00939 doi:10.14309/crj.0000000000000939.

    PMID: 36600788
  21. 21

    Primary Intestinal Lymphangiectasia as a cause of secondary combined immunodeficiency: case study and literature review.

    Hall RM, Panton LA, Ineus L, et al.

    Clinical immunology communications 2026; (9()):133-137 doi:10.1016/j.clicom.2026.05.002.

    PMID: 42416886
  22. 22

    Primary intestinal lymphangiectasia with generalized warts.

    Lee SJ, Song HJ, Boo SJ, et al.

    World journal of gastroenterology 2015; (21(27)):8467-72 doi:10.3748/wjg.v21.i27.8467.

    PMID: 26217101

This page is for informational purposes only and does not constitute medical advice. A specialist team should determine whether these treatments, procedures, or infusions are appropriate for your primary intestinal lymphangiectasia.